Keywords: gsk, initiates, ph, iii, hep, promacta, studies

GSK initiates Ph III hep C Promacta studies

Article | 21 November 2007

Print This

UK drug major GlaxoSmithKline says it has begun two parallel Phase III studies designed to evaluate Promacta/ Revolade (eltrombopag) in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in